ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Based on its recent analysis of the clinical diagnostics market, Frost & Sullivan recognized GenPath Diagnostics, a business unit of BioReference Laboratories, Inc ...
Kenneth Weg, former vice chairman of Bristol-Myers Squibb, first heard the details about a technology to prioritize the best drug targets about a year ago. Raju Kucherlapati, a fellow member of the ...
Cambridge-based GenPath Pharmaceuticals Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has entered into a multi-year ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (“BRLI”) (NASDAQ: BRLI) announced today that it has completed an equity investment in InCellDx, Inc. (“InCellDx”), a privately ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...
Less than a month after raising $42.7 million in a Series B round, GenPath Pharmaceuticals Inc. said it has nailed down a multiyear cancer deal with Merck & Co. Inc. worth up to $100 million, ...
Bio-Reference Laboratories, Inc. has announced that K-ras mutation testing for patients with metastatic colorectal (mCRC) or non-small-cell lung (NSCLC) cancers will now be available through the ...
Little more than a year after starting a business based on spontaneous tumor models in mice, GenPath Pharmaceuticals Inc. raised $42.7 million in a Series B financing. (BioWorld Today) ...
CAMBRIDGE, Mass. -- Closely held GenPath Pharmaceuticals Inc. said it signed a multiyear agreement with Merck & Co. covering its cancer-research techniques that has a potential value of $100 million ...
GenPath Pharmaceuticals Inc., Cambridge, Mass., raised $42.7 million in series B funding. Flagship Ventures led the round, which included Highland Capital Partners, Oxford Biosciences, existing ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback